An Open Label, Phase 2 Study to Assess the Clinical Efficacy and Safety of Daratumumab in Patients With Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2017
At a glance
- Drugs Daratumumab (Primary)
- Indications Lymphoma
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 06 Apr 2017 Planned End Date changed from 3 Jan 2020 to 22 Aug 2019.
- 06 Apr 2017 Status changed from not yet recruiting to recruiting.
- 27 Jan 2017 Planned initiation date changed from 1 Jan 2017 to 1 Feb 2017.